Study to Assess the Safety & Efficacy of Oral Ciprodiazole Versus Currently Used Ciprofloxacin & Metronidazole

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

312 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-17

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to assess the safety \& efficacy of Oral Ciprodiazole® versus currently used Ciprofloxacin Tablets \& Metronidazole tablets in pelvi-abdominal infections and following IV antibiotics in post-operative period, for pelvi-abdominal surgeries or acute conditions

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Antibiotic Treatment Trial for Small Intestinal Bacterial Overgrowth

NCT02458781

Small Intestinal Bacterial Overgrowth

UNKNOWN PHASE4

A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection

NCT01473836

Intra-abdominal Infections

COMPLETED PHASE3

Metagenomic and Metabolomic Reconstitution of Gut Microbiota After Broad Spectrum Antibiotic Therapy

NCT04171466

Antibiotic Side Effect Antibiotic-associated Diarrhea Antibiotic-induced Dysbiosis +1 more

COMPLETED NA

A Multicentre, Randomized as a Double Blind Study, Triple Placebo, Comparative of the Efficacy and Safety of an Association Secnidazol-Ciprofloxacin Compared With Amoxicillin-Clavulanic Acid for the Treatment of Uncomplicated Episode of Diverticular Sigmoïditis Among Adults

NCT01733966

Diverticular Sigmoïditis

TERMINATED PHASE3

A Study of Ascending Multiple Doses of Oral Surotomycin in Healthy Participants (MK-4261-009)

NCT02835118

Clostridium Difficile Associated Diarrhea (CDAD)

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Objective

1. Primary Safety:

To compare safety of oral Ciprodiazole ® tablets (Ciprofloxacin/Metronidazole) versus currently used Ciprofloxacin Tablets \& Metronidazole tablets for pelvi-abdominal infections, either non-operative or post-operative following IV antibiotics.
2. Primary Efficacy:

To compare efficacy of oral Ciprodiazole ® tablets (Ciprofolxacin/Metronidazole) versus currently used Ciprofloxacin Tablets \& Metronidazole tablets for pelvi-abdominal infections, either non-operative or post-operative following IV antibiotics.

Secondary Objective

1. Secondary Safety:

* Presence of any signs/symptoms of post-operative wound infection such as redness, fever or wound discharge.
* Presence of undesirable effects on total leukocyte count and liver enzymes (SGOT\& SGPT)
2. Secondary Efficacy:

* To compare the complete resolution or improvement of Pelvi-abdominal infection between ciprodiazole® versus combined treatment, based on pelvi-abdominal ultrasound and others
* To compare the days for complete healing of post-operative wounds between ciprodiazole® versus combined treatment

STUDY DURATION:

* Subjects will be enrolled for 12 months including screening visit
* Follow up for 15 days from enrolment

STUDY POPULATION:

312 Egyptian Patients with pelvi-abdominal infection or started IV antibiotics in post-operative period, for pelvi - abdominal surgeries and/or acute conditions

ASSESSMENT SCHEDULE:

Subjects will be enrolled for 12 months including screening visit

* Visit 1: Screening and treatment initiation visit, Day 0
* Follow-up 1 visit: Day 8 (+/-) 3 days
* Follow-up 2 visit \& End of study visit: Day 15 (+/-) 3 days

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Surgical Site Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

They will be randomized by computer, into 2 treatment groups; Ciprodiazole ® tablets (Ciprofloxacin/Metronidazole) versus currently used Ciprofloxacin Tablets \& Metronidazole tablets

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ciprodiazole

Ciprodiazole Tablets: (Ciprofloxacin 500 mg \& Metronidazole 500 mg), 1 tablet every 12 hours up to 15 days

Group Type EXPERIMENTAL

Ciprodiazole

Intervention Type DRUG

Ciprofolxacin 500 mg / Metronidazole 500 mg

Ciprofloxacin 500 mg Tablets & Metronidazole 500 mg tablets

Ciprofloxacin 500 mg Tablets: 1 tablet every 12 hours up to 15 days

Metronidazole 500 mg tablets: 1 tablet every 8 hours up to 10 days

Group Type ACTIVE_COMPARATOR

Ciprofloxacin Tablets & Metronidazole tablets

Intervention Type DRUG

Ciprofolxacin 500 mg + Metronidazole 500 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ciprodiazole

Ciprofolxacin 500 mg / Metronidazole 500 mg

Intervention Type DRUG

Ciprofloxacin Tablets & Metronidazole tablets

Ciprofolxacin 500 mg + Metronidazole 500 mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Egyptian male and female patients aged between 18-65 years' old
2. Subjects having pelvi-abdominal infections such as and not limited to: Ulcerative Colitis, Diverticulitis, Cholecystitis and Pelvic Inflammatory Diseases (PID), as oophoritis and salpingo-oophoritis.
3. Subjects during post-operative period for pelvi-abdominal surgery and following IV medication with Metronidazole injection plus third generation cephalosporin.
4. Subjects who are willing to sign Informed Consent Form (ICF) and ready to comply with the protocol for the duration of the study

Exclusion Criteria

1. Subjects with a history of hypersensitivity to any of the active ingredients of the treatments used
2. Subjects who are receiving or received any other antibiotics during the previous two weeks, rather than IV treatment in the first post-operative 48 hours, mentioned in the protocol
3. Subjects with Pelvi-abdominal infection and performed surgery after failure of oral antibiotics.
4. Subjects having surgeries such as colorectal surgeries.
5. Subjects with any medical condition requiring the usage of the following medications:

* Drugs that induce microsomal liver enzymes, such as Phenytoin or Phenobarbital.
* Drugs that decrease microsomal liver enzymes activity, such as cetrimide.
* Theophylline
* Corticosteroids
* Antacids containing magnesium and aluminum, supplements and other products containing calcium, iron or zinc
* Tizanidine
6. Subjects with uncontrolled diabetes mellitus; FBG \> 200 mg/ml
7. All subjects with renal impairment (S. Creatinine \> 1.5 mg/dL)
8. All subjects with hepatic impairment (Child-Pugh Score B-C)
9. Subjects with liver enzymes (SGOT \& SGPT \> 2 Normal range)
10. Pregnant or breast-feeding women

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No